Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Sarcoma 1Recurrence 1Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 128Radiotherapy 85Bevacizumab 43Radiation 30Carmustine 29Irinotecan 25Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14sargramostim 12Radiotherapy, Intensity-Modulated 12Radiotherapy, Conformal 12Sirolimus 10Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8pembrolizumab 8Thalidomide 8Sorafenib 8Radiosurgery 8Gefitinib 8motexafin gadolinium 7aldesleukin 7Procarbazine 7Gene Expression Profiling 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × nintedanib × Sarcoma × Clear all
NCT01380782 2014-08-18

BIBF 1120 for Recurrent High-Grade Gliomas

Dana-Farber Cancer Institute

Phase 2 Completed
37 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Recurrence, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡